Oncology-focused AI solutions platform developer Precision Health AI (PH.AI) said today it is partnering with oncology research and data analytics company Vector Oncology to launch a cancer data partnership, with the goal of creating the largest and best set of “real-world” cancer data.
PH.AI said the partnership is intended to demonstrate the effectiveness, safety, and value of oncology therapeutics by drawing upon its alliance with CancerLinQ, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO).
In December, CancerLinQ inked a license agreement with PH.AI and another data services company, Tempus, by which the two agreed to curate data into datasets intended for use in cancer care and research, to be made available through the core CancerLinQ quality improvement platform.
“We now put the power of CancerLinQ data—enhanced with both descriptive and prescriptive AI metadata and Vector Oncology's proprietary data—to work for the benefit of the industry and the people it serves,” Romesh Wadhwani, founder and CEO of PH.AI parent company SymphonyAI, said in a statement.
Vector Oncology serves 15 undisclosed “top” pharmaceutical companies by designing and executing retrospective and multi-year hybrid studies to enroll targeted cohorts of patients in active treatment. The company says the studies are intended to deliver real-time, clinical research quality, “real-world” insights on treatment patterns, comparative effectiveness, health outcomes, and economics.
“Vector Oncology brings comprehensive existing data, including retrospective and multi-year hybrid studies, and a world-class curation team comprised of oncology nurse abstractors and exclusive curators,” added PH.AI CEO Brigham Hyde, Ph.D. “The richness this provides to our Eureka Health Oncology platform can't be overstated.”
Eureka Health Oncology is designed to provide practical AI applications for oncology use cases. The technology uses data from electronic health records and other sources to help researchers and clinicians design targeted therapies, shape clinical trials, and determine what therapies offer the greatest patient benefits.
The announcement comes days before ASCO’s 2018 Annual Meeting, set for June 1-5 in Chicago. PH.AI said executives from the company, its parent SymphonyAI, and Vector Oncology will be at ASCO Booth 25109, meeting with pharmaceutical companies.